[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progressive-supranuclear-palsypsp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progressive-supranuclear-palsypsp":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,72,99,129,170,193],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100611455","digital-health-technologies-for-progressive-supranuclear-palsy-and-dementia-with-lewy-bodies-100611455",false,"NCT07240805","Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Digital Health Technologies For Monitoring Disease Symptoms in Progressive Supranuclear Palsy and Dementia With Lewy Bodies","Inclusion Criteria:\n\n* Male and female participants aged 40-89 meeting clinical diagnostic criteria for probable PSP, probable MCI-LB or probable DLB.\n* Able to be present for all study procedures, complete questionnaires and assist during home data collection.\n* Eligible participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n* Ambulatory (able to take 10 steps with minimal support such as use of a cane)\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* History of frequent falls defined as more than 5 falls per month, will not be eligible to participate in the study.","ALL","40 Years","89 Years",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily function. Researchers at BioSensics, Johns Hopkins School of Medicine, Massachusetts General Hospital and their collaborators aim to conduct an analytical and clinical validation of wearable-based digital health technologies for monitoring upper and lower limb function in PSP, MCI-LB and DLB that could enable frequent, at-home monitoring and be incorporated into future clinical trials.",[25,26,27,28,29],"Progressive Supranuclear Palsy(PSP)","Dementia With Lewy Bodies (DLB)","PSP","Lewy Body Dementia (LBD)","Lewy Body Disease","NOT_YET_RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":21},"2026-06-15",{"date":38,"type":21},"2029-01-01",{"name":40,"class":41},"BioSensics","INDUSTRY",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100606303","phase-2-the-progressive-supranuclear-palsy-clinical-trial-platform-100606303","NCT07173803","The Progressive Supranuclear Palsy Clinical Trial Platform","PTP","Inclusion Criteria:\n\n1. Clinical diagnosis of possible or probable PSP Richardson's Syndrome as defined by the 2017 Movement Disorder Society (MDS) criteria.\n2. Presence of PSP symptoms for ≤5 years at screening (based on the best judgment of the site PI).\n3. Mini-Mental State Examination (MMSE) score at screening of ≥25.\n4. Able to walk at least 10 steps with minimal assistance (e.g., one arm for safety, but not postural support).\n5. Stable doses of permitted medications as described per protocol for 30 days prior to screening.\n6. Resides at home or in the community (assisted living is acceptable).\n7. As assessed by the site PI, participant is likely to be able to comply with the protocol for the duration of the study, and has adequate vision, hearing (hearing aid permitted), and literacy (English or Spanish) sufficient for compliance with the required testing procedures.\n\nExclusion Criteria:\n\n1. Females who are breastfeeding or pregnant (as documented by a urine pregnancy test) during screening, or plan to become pregnant during the study.\n2. Females of childbearing potential who did not use a highly effective method of contraception within 28 days of screening and\u002For are not willing to use a highly effective method of contraception for the duration of their participation in the study.\n3. Lacks good venous access such that multiple blood draws would be precluded.\n4. Weighs less than 40kg, or more than 136kg at screening.\n5. Blood transfusion within 4 weeks of screening.\n6. Contraindications to MRI studies, including metal (ferromagnetic) implants, a cardiac pacemaker that is not compatible with MRI, and\u002For severe claustrophobia.\n7. Screening MRI scan showing structural evidence of alternative pathology not consistent with PSP that could explain a substantial portion of the participant's symptoms as indicated by the central MRI read.\n8. Any unstable and\u002For clinically significant medical condition likely to hamper the evaluation of safety and\u002For efficacy of study drug (e.g., clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular or cardiovascular conditions), as per the site PI's judgment.\n9. History of severe allergic reaction (e.g., anaphylaxis) including but not limited to: severe allergic reaction to previous vaccines, foods, and\u002For medications.\n10. Hospitalization within 30 days prior to screening or baseline.\n11. Infections or major surgical procedures within 3 months prior to screening, judged to be clinically significant by the site PI.\n12. Myocardial infarction within 1 year prior to baseline, unstable angina pectoris, symptomatic congestive heart failure.\n13. History of cancer within the past 5 years other than treated skin squamous cell carcinoma, basal cell carcinoma, and melanoma in-situ, localized prostate cancer not requiring treatment, or prostate or breast cancer, which have been fully removed and are considered cured.\n14. History or presence of immunological or inflammatory conditions, including neurological disorders, meningitis or meningoencephalitis.\n15. History or presence of epilepsy requiring ongoing use of antiepileptic medications. Antiepileptic medications are permitted for pain or psychiatric use per the protocol.\n16. DSM-5 criteria for drug or alcohol abuse or dependence currently met within the past 5 years.\n17. Clinically significant abnormal vital signs including sustained sitting blood pressure \\>160\u002F100 mm Hg.\n18. Diabetes mellitus with hemoglobin A1c (HbA1c) levels of ≥8.0%.\n19. Known history of human immunodeficiency virus (HIV-1 or 2).\n20. Known history of acute\u002Fchronic hepatitis B or C unless treated curatively.","41 Years","86 Years",{"count":53,"type":21},440,"INTERVENTIONAL",[56],"PHASE2","The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.",[25],[27,60,61,62],"Placebo-Controlled","Double-Blind","Master Protocol","2026-04-24",{"date":65,"type":34},"2026-04-27",{"date":31,"type":21},{"date":68,"type":21},"2030-09-28",{"name":70,"class":71},"Adam Boxer","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100623113","study-on-artificial-intelligence-based-facial-and-speech-related-patterns-in-parkinsons-disease-and-their-digital-biomarkers-100623113","NCT07392411","Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers","Inclusion Criteria:\n\n1. Inclusion Criteria for Parkinson's Disease (PD) Group: (1) Diagnostic Criteria: Meet the diagnostic criteria for Parkinson's disease established by the Movement Disorder Society (MDS) in 2015. (2) Age Range: 18-75 years old. (3) Disease Severity: Early-stage PD: Hoehn-Yahr score ≤ 2.5 points. Mid-to-late-stage PD: Hoehn-Yahr score 2.5-5 points. (4) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (5) Informed Consent: Signed informed consent form.\n2. Inclusion Criteria for Parkinson's Plus Syndromes (MSA-P, PSP) Group: (1) Age Range: 18-75 years old. (2) Diagnostic Criteria: MSA patients must meet the diagnostic criteria established by the \\[Chinese Expert Consensus on the Diagnosis of Multiple System Atrophy, 2017\\]. PSP patients must meet the diagnostic criteria established by the \\[Chinese Clinical Diagnostic Criteria for Progressive Supranuclear Palsy, 2016 Edition\\]. (3) Consent for Data Collection: Willing to undergo facial expression video and speech audio recording. (4) Informed Consent: Signed informed consent form.\n\nExclusion Criteria:\n\n1. History of cerebrovascular disease, head trauma, hydrocephalus, brain tumors, or intracranial surgery.\n2. Presence of metal implants, cardiac pacemakers, or other metallic foreign bodies (applies to PD patients).\n3. Severe dyskinesia in PD patients that would compromise cooperation with video\u002Faudio recording.\n4. Mini-Mental State Examination (MMSE) score ≤ 24 points.",true,"15 Years","75 Years",{"count":82,"type":21},720,"This research employs AI to analyze facial expressions and speech patterns, aiming to develop new digital tools for diagnosing and differentiating Parkinson's disease and similar disorders.",[85,25,86,87],"Parkinson's Disease","Multiple System Atrophy","Healthy Control","RECRUITING","2026-01-30",{"date":91,"type":34},"2026-02-06",{"date":93,"type":34},"2023-07-25",{"date":95,"type":21},"2026-12-31",{"name":97,"class":71},"Beijing Tiantan Hospital",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":78,"sex":16,"minAge":107,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":98},"100417416","upenn-observational-research-repository-on-neurodegenerative-disease-100417416","NCT04715399","UPenn Observational Research Repository on Neurodegenerative Disease","University of Pennsylvania Centralized Observational Research Repository on Neurodegenerative Disease (UNICORN)","UNICORN","Inclusion Criteria:\n\nThis protocol will include 3 groups of people:\n\n1. People with a clinical diagnosis of a neurodegenerative disease. such as frontotemporal degeneration(FTD), primary progressive aphasia(PPA), Lewy body disease(LBD), amyotrophic lateral sclerosis(ALS), progressive supranuclear palsy(PSP), corticobasal syndrome(CBS), posterior cortical atrophy(PCA), Alzheimer's disease(AD), Parkinson's disease(PD)\n2. People with a family history of neurodegenerative disease who may or may not be symptomatic, and may or may not be mutation carriers such as familial frontotemporal lobar degeneration (fFTLD) or familial ALS,\n3. People with no known neurological disease who will provide control data.\n\nExclusion Criteria:\n\n* Anyone who is under the age of 18.\n* Anyone with a condition or in a situation which, in the Investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological and other medical conditions (such as cardiac, neurosurgical, infectious conditions).\n* Individual participants may be excluded from some, but not all, study procedures for safety reasons when they have a contraindication or at the discretion of the Investigator. For example, persons with metal implants which are not MRI-safe will not be able to take part in imaging, and those on blood thinning medications may not be able to take part in lumbar puncture.\n* Pregnant women; if a woman becomes pregnant during the study, research activities that may increase risk to the patient and the unborn fetus will be stopped until the end of pregnancy, at which point participation can be resumed.","18 Years",{"count":109,"type":21},1000,"The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.",[112,113,114,115,116,25,117,118,119],"Frontotemporal Degeneration(FTD)","Primary Progressive Aphasia(PPA)","Familial Frontotemporal Lobar Degeneration (fFTLD)","Amyotrophic Lateral Sclerosis(ALS)","Lewy Body Disease(LBD)","Corticobasal Syndrome(CBS)","Posterior Cortical Atrophy(PCA)","Alzheimer's Disease(AD)","2026-01-21",{"date":122,"type":34},"2026-01-22",{"date":124,"type":34},"2020-05-29",{"date":126,"type":21},"2070-05-30",{"name":128,"class":71},"University of Pennsylvania",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":78,"sex":16,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":155,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":98},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.","35 Years",{"count":109,"type":21},"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[27,139,140,117,141,142,143,144,145,146,147,86,148,149,150,151,152,153,25,154],"PSP - Progressive Supranuclear Palsy","Corticobasal Syndrome","Corticobasal Degeneration Syndrome","Corticobasal Degeneration","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy (PSP)",[156,153,86,157,158,27,145,159,160],"genetic study","Corticobasal","CurePSP","CBD","Genes","2026-01-12",{"date":163,"type":34},"2026-01-14",{"date":165,"type":34},"2024-10-08",{"date":167,"type":21},"2030-12-31",{"name":169,"class":71},"Massachusetts General Hospital",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":191,"locationsCount":98},"100603838","collection-of-digital-parameters-from-parts-of-the-neurological-examination-using-an-eye-tracker-100603838","NCT07141719","Collection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker","A Digital Protocol for Neurological Examination Using Eye-Tracking","NEX-Eye","Inclusion Criteria:\n\n* ≥ 18 years of age.\n* Diagnosed or treated for a neurological disease.\n* Hospitalized or outpatient of the Department of Neurology, UKSH Campus Kiel.\n* Ability of the person to understand oral study information and study information sheet, and willingness to provide a signed and dated informed consent form.\n\nExclusion criteria:\n\n* Being under legal guardianship\n* Impaired decision-making capacity, or temporal or spatial disorientation which may be revealed within ordinary conversation or by a confirmed diagnosis of dementia. In case of doubt, the Montreal Cognitive Assessment (MoCA, pass cutoff score \\> 18 16) will be administered.",{"count":179,"type":21},600,"The neurological examination (NE) is a cornerstone of clinical neurology, with ocular motor assessment being a key component. Technology offers an opportunity to augment and standardize parts of the NE. Eye-tracking systems provide objective quantitative data on eye movements by continuously tracking the eye over time. This data can be used to derive parameters like saccadic latency, gaze velocity, and fixation stability with a precision that is impossible to achieve through human observation by neurologists. The integration of such technology could enhance the traditional NE.\n\nBefore such technology can be widely adopted, its feasibility and acceptability in a clinical population must be established. The primary purpose of this study is to assess the usability of a novel eye-tracking system from the patient's perspective when used in a clinical settings. A secondary purpose is to determine if quantitative data from the eye-tracker correlate with the findings of the traditional clinical neurological examination and to explore whether eye-tracking can provide additional, complementary information not typically captured by standard clinical assessment.\n\nTo achieve these aims, the study will assess several outcome measures. The primary outcome measure is the Usability of the Eye-Tracking System, which will be measured using the System Usability Scale (SUS).\n\nBeyond the primary objectives, this study will investigate two secondary objectives.\n\nThe first involves assessing the relationship between quantitative eye-tracking parameters and clinical ocular motor assessment. Specifically, the investigators will analyze objective, numerical data obtained from eye-tracking systems and the clinician's subjectively graded assessment of ocular movements derived from the standard neurological examination.\n\nThe second is the exploratory analysis of novel eye-tracking biomarkers. This involves quantifying and analyzing eye-tracking parameters not typically assessed during a routine NE. For example, the dynamics of the pupillary light reflex or the frequency of microsaccades. The aim is to identify potential digital biomarkers that could provide additional objective insights into ocular motor function and neurological status.",[182,183,25,184],"Geriatric","Parkinsons Disease (PD)","Neurological Diseases or Conditions","2025-08-24",{"date":187,"type":34},"2025-08-26",{"date":189,"type":21},"2025-08-31",{"date":95,"type":21},{"name":192,"class":71},"University of Kiel",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":200,"maxAge":80,"enrollmentInfo":201,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":98},"100589088","ai-enhanced-optimization-of-acute-levodopa-challenge-test-100589088","NCT06949865","AI-Enhanced Optimization of Acute Levodopa Challenge Test","Clinical Research on Optimization of Acute Levodopa Challenge Test and Exploration of New Motor Paradigm Based on the Integration of Perception Technology and Artificial Intelligence","Inclusion Criteria:\n\n1. Parkinson's disease (PD) group: 1. Patients with confirmed Parkinson's disease diagnosed based on the 2015 International Movement Disorder Society (MDS) Parkinson's Disease Diagnostic Criteria; 2. Patients with early-stage PD meet the Hoehn-Yahr score ≤ 2.5 points, and patients with intermediate and advanced PD meet the Hoehn-Yahr score of 2.5-5 points; 3. Subjects are 50-75 years old (including boundary values), gender is not limited; 4. Agree to undergo study-related examination evaluation and sign informed consent.\n2. Multiple system atrophy (MSA) group : 1. Patients with confirmed or probable MSA diagnosed based on the diagnostic criteria for MSA published by the International Movement Disorder Society (MDS) in 2022 ;2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n3. Progressive supranuclear palsy (PSP) group: 1. Patients with confirmed or probable PSP diagnosed based on the diagnostic criteria of the 2017 International Movement Disorder Association PSP Collaborative Group; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n4. Vascular parkinsonism (VP) group: 1. In line with the diagnostic recommendations of vascular parkinsonism in accordance with the 2004 International Association for Movement Disorders and the 2017 Chinese expert consensus; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n5. Drug-induced parkinsonism (DIP) group: 1. Parkinsonism; 2. Drug history, the appearance of symptoms is related to specific drugs; 3. Symptoms are reversible, and the symptoms are reduced or disappeared when the corresponding drugs are reduced; 4. Rule out other causes; 5. Subjects are 50-75 years old (including boundary values), gender is not limited; 6. Agree to undergo study-related examination evaluation and sign informed consent.\n6. Corticobasal degeneration (CBD) group: 1. Diagnosis of probable or probable CBD based on the 2019 Chinese diagnostic criteria for corticobasal degeneration; 2. Subjects are 50-75 years old (including boundary values), gender is not limited; 3. Agree to undergo study-related examination evaluation and sign informed consent.\n7. Dementia with Lewy Bodies (DLB) Group: 1. Diagnosed as probable or possible DLB based on the 2017 international DLB diagnostic criteria and the 2021 Chinese DLB diagnostic criteria. 2. Exhibits symptoms of Parkinsonism. 3. Subjects are aged 50-75 years (inclusive), with no gender restriction. 4. Agree to undergo study-related assessments and evaluations and signs the informed consent form.\n\nExclusion Criteria:\n\n1. Cognitive dysfunction, unable to complete the study (MMSE \\\u003C 23)\n2. Inability to tolerate levodopa shock test\n3. Patients with failure of important organs (heart, lung, liver, kidney, etc.), malignant tumors, unstable conditions and other serious internal diseases\n4. Those with serious behavioral problems or mental disorders\n5. Inability to sign informed consent\n6. Other conditions that are considered unsuitable by the investigator to participate in this study.","50 Years",{"count":202,"type":21},2000,"A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.",[205,206,143,207,208,25,209],"Vascular Parkinsonism","Drug-induced Parkinsonism","Parkinson Disease (PD)","Dementia With Lewy Body Disease","Multiple System Atrophy (MSA)","2025-04-22",{"date":212,"type":34},"2025-04-29",{"date":214,"type":34},"2024-05-28",{"date":95,"type":21},{"name":97,"class":71}]